Verastem (NASDAQ: VSTM) just reported results for the fourth quarter of 2023. Verastem reported earnings per share of -$1.10. This was below the analyst estimate for EPS of -62 cents. The company ...Verastem Oncology is currently conducting clinical trials with its RAF/MEK clamp avutometinib in RAS/MAPK driven tumors as part of its (Raf And Mek Program). RAMP 301 (NCT06072781) is a Phase 3 confirmatory trial evaluating the combination of avutometinib and defactinib versus standard chemotherapy or hormonal therapy for the …Inside Verastem, Inc.'s 10-K Annual Report: Other - Other Highlight. For example, if the FDA or other regulatory authority were to require us to conduct clinical trials beyond those which we currently anticipate will be required for the completion of clinical development of a product candidate or if we experience significant delays in enrollment in any clinical trials, we could be required to ...

Track Aeva Technologies Inc (AEVA) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsVerastem Oncology Outlines Key 2022 Strategic Priorities and Upcoming Catalysts for Advancing VS-6766 as a Backbone of Therapy for RAS Pathway-Driven Cancers. PDF Version. Report Selection Phase (Part A) Results from RAMP 201 and RAMP 202 Evaluating VS-6766 Alone and in Combination with Defactinib in Low-Grade Serous …Verastem Oncology (Nasdaq: VSTM) is a commercial biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and ...

annika hrycuna Verastem (VSTM) avutometinib in combination with Amgen's Lumakras has received FDA fast track status in the treatment of a certain type of lung cancer. Read more here. ilab wcmcwisconsin volleyball leak hub Verastem Oncology, a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced a potential best-in-class KRAS G12D oral inhibitor as the lead program ...Mr Paterson joined Verastem Oncology in 2011 and was its President and Chief Operating Officer prior to becoming President and Chief Executive Officer in 2023. He has more than 30 years of experience at healthcare and biotechnology companies, including leadership roles as Chief Business Officer (CBO), Chief Operating Officer (COO) and Chief ... mendeecees net worth 2023 Verastem Oncology (Nasdaq: VSTM) is a commercial biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and ... 866 928 8598jason aldean sues whoopi goldbergweather in salina kansas 10 days Free VSTM Stock Alerts. $11.50. -0.63 (-5.19%) (As of 05/17/2024 08:54 PM ET) Compare. Share. Stock Analysis Analyst Forecasts Chart Competitors Earnings Financials Headlines Insider Trades Options Chain Ownership SEC Filings Short Interest Social Media. Media Mentions Over Time. 10.Investors. At Verastem Oncology, Inc. (NASDAQ: VSTM), we’re working to develop a portfolio of novel small-molecule drugs that inhibit critical RAS signaling pathways that promote cancer cell survival and tumor growth. We’re pushing beyond what’s known about cancer treatment and working to deliver novel treatment approaches that address ... best fast food okc However, these revenue estimates do illustrate how Verastem could go from pulling just over $2M to over $200M in just five years, which would be a roughly 0.4x forward price-to-sales. The industry ... 19754 e 35th drbotw flintbest spt mods Shares of Verastem, Inc. (NASDAQ:VSTM – Get Free Report) have been assigned an average recommendation of “Buy” from the six brokerages that are covering the firm, Marketbeat.com reports.Six investment analysts have rated the stock with a buy recommendation. The average 1-year price target among brokers that have issued …Verastem, Inc. (NasdaqCM:VSTM) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds (or held) more than 5% ...